To our knowledge, so far, no specific 5hmC biomarker of response to cancer therapy has been validated, although several lines of evidence suggest the involvement of TET enzymes in the response mechanisms; for example, TET1 knockdown in lung cancer cell lines with EFGR mutations leads to enhanced EFGR inhibitor resistance, while the responsive tumors show increased TET1 expression [179]. The gene discussed is TET1; the disease is cancer.